Some Products May Appear Restricted
To ensure a smooth and speedy checkout, please log in to your account. Some items may show as restricted simply because you're not logged in.
If you do not have an account, you can register using our registration webform (https://www.avantorsciences.com/us/en/login/register)
If you're still seeing restrictions after logging in, certain products—like chemicals or medical devices—require additional account verification steps to be able to place an order. Some items may additionally require a specific license or customer documentation; additional documentation will be requested for these items prior to shipment.
Specifications
- Description:Anti-ß2 GP-1 screen (Beta 2 Glycoprotein 1) ELISA
- Size:1 kit
- Cat. No.:102993-950
- Supplier no.:B2S31-K01
Specifications
About this item
Anti-Beta 2 GP-I Screen ELISA determines IgG,IgM and IgA Ab (screening) to Beta2 glycoprotein-I.
- Dynamic Range: 10-300 U/mL
- Sensitivity: Cut-off
- Incubation: 2.5 hours
APAS is an autoimmune disorder comprising such clinical symptoms like arterial or venous thrombosis, thrombocytopenia and recurrent fetal loss. Primary APAS as well as systemic lupus erythematosus (SLE) are characterized by the appearance of autoantibodies to negatively charged phospholipids (1). Although significance and pathological relevance of phospholipid anti¬bodies are not completely revealed yet, the detection of several autoantibody specificities is usually applied to the differential diagnosis and follow-up of systemic rheumatic inflammatory diseases. Unlike phospholipid antibodies which occur in some patients having infectious disease, phospholipid antibodies of autoimmune disease patients seem to recognize the relevant phospholipids in association with a plasma protein cofactor. One of these cofactors has been identified as 2 glycoprotein-I (2 GP-I) (apo¬lipo¬pro¬tein H) (2,3). 2 GP-I, a serum protein with a molecular weight of 50 kDa affects platelet aggregation and coagulation. The positively charged fifth domain of 2 GP-I interacts with negatively charged phospholipids or activated polystyrol surfaces of ELISA wells. This interaction results in conformational changes of 2 GP-I and the creation of new epitopes apparently recognized by autoimmune phospholipid autoantibodies.